Table 4. Comparison of warnings and precautions for dalbavancin, oritavancin, telavancin, and vancomycin^1,4,5,6.

Warnings and precautions	Dalbavancin	Oritavancin	Telavancin	Vancomycin
ALT elevation	X
CDAD	X	X	X	X
C. diffcile-induced pseudomembranous colitis				X
Chemical peritonitis associated with intraperitoneal administration				X
Development of drug-resistant bacteria	X	X	X	X
Hypersensitivity reactions	X	X	X
Hypersensitivity reactions with prior vancomycin or other glycopeptide therapy	X	X	X	X
Increased mortality in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia			X
Infusion-related events (eg, f ushing, erythema, urticaria, pruritus)	X	X	X	X
Injection-site pain				X
Interference with coagulation test results		X	X
Intrathecal or intraperitoneal administrationa				X
Nephrotoxicity			X	X
Neutropenia, reversible				X
Osteomyelitis		X
Ototoxicity				Xb
QTc prolongation			X
Rapid bolus administration	X		X	X
Reduced eff cacy in patient with moderate/severe preexisting renal impairment			X
Renal impairment, dosage adjustment			X	X
Thrombophlebitis				X
Special populations
Pregnancy Category	Category C	Category C	Category C	Category C
Breast-feeding	Unknown	Unknown	Unknown	Caution
Pediatric use	No data	No data	No data	Yes

Note: ALT = alanine aminotransferase; CDAD = C. difficile-associated diarrhea; C. difficile = Clostridium difficile.

^aEfficacy not established by adequate and well-controlled trials.

^bPatients receiving excessive doses, who have underlying hearing loss, or who are receiving concurrent therapy with another ototoxic drug (eg, aminoglycosides).